促纤维增生性黑色素瘤中PDL1表达与肿瘤侵袭性和进展相关
该研究在66例促纤维增生性黑色素瘤中分析PDL1、p53、Ki-67表达与CD8+及FoxP3+免疫浸润、临床病理变量及患者结局的相关性。结果显示21%(14/66)患者肿瘤PDL1表达≥25%,与混合组织学、肿瘤厚度、核分裂、复发和转移显著相关,且PDL1≥25%与更短无进展生存和黑色素瘤特异性生存相关。
要点
- 21%促纤维增生性黑色素瘤肿瘤PDL1表达≥25%,与侵袭性特征相关。
- PDL1≥25%独立预测更短无进展生存,混合组织学亦为独立预测因子。
- 肿瘤和间质CD8+及FoxP3+淋巴细胞计数与肿瘤PDL1表达相关。
核心结论
- 促纤维增生性黑色素瘤中肿瘤PDL1表达与肿瘤侵袭性和进展相关。
- 肿瘤和间质CD8+及FoxP3+淋巴细胞计数与肿瘤PDL1表达相关,支持适应性免疫反应。
- PDL1表达频率和水平可能识别出可能对免疫治疗有反应的黑色素瘤亚群。
研究设计与样本
- 研究系列包含66例促纤维增生性黑色素瘤。
- 将PDL1、p53和Ki-67表达与CD8+和FoxP3+免疫浸润、临床病理变量及患者结局进行相关性分析。
主要发现
- 肿瘤PDL1表达≥25%见于21%患者(14/66),与混合组织学、肿瘤厚度、核分裂、复发和转移显著相关。
- 线性回归分析显示肿瘤PDL1表达与厚度(P = .0041)、p53表达(P = .019)、Ki-67增殖指数(P = .0018)、肿瘤CD8(P = .0084)、间质CD8(P < .0001)和FoxP3(P < .0001)T细胞计数相关。
- 单因素分析显示PDL1表达≥25%与更短无进展生存(P < .0001)和黑色素瘤特异性生存(P = .034)相关。
- 多因素分析显示PDL1表达≥25%(P = .026)和混合组织学(P = .039)独立预测更短无进展生存,淋巴血管侵犯预测更短总生存(P = .018)。
临床怎么用
- 在促纤维增生性黑色素瘤中评估PDL1表达可能有助于识别侵袭性更强、进展风险更高的患者。
- PDL1表达频率和水平可能用于筛选可能从免疫治疗中获益的黑色素瘤患者亚群。
局限性
- 研究样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The prognostic role of programmed death ligand 1 (PDL1), CD8, and forkhead box p3 (FoxP3) expression in desmoplastic melanomas is unclear. METHODS: We correlated PDL1, p53, and Ki-67 expression with CD8+ and FoxP3+ immune infiltrates with clinicopathologic variables and patient outcomes in a series of 66 desmoplastic melanomas. RESULTS: Tumoral PDL1 expression (≥25%), which was seen in 21% of patients (14 of 66), significantly correlated with mixed histology, tumor thickness, mitoses, recurrence, and metastasis. According to linear regression analysis, tumoral PDL1 expression correlated with thickness (P = .0041); p53 expression (P = .019); Ki-67 proliferation index (P = .0018); and tumoral CD8 (P = .0084), stromal CD8 (P < .0001), and FoxP3 (P < .0001) T-cell counts. According to univariate analyses, PDL1 expression of 25% or higher correlated with shorter progression-free survival (P < .0001) and melanoma-specific survival (P = .034). According to multivariate analyses, PDL1 expression of 25% or more (P = .026) and mixed histology (P = .039) independently predicted shorter progression-free survival, and presence of lymphovascular invasion predicted shorter overall survival (P = .018). LIMITATIONS: Small study size. CONCLUSION: Tumoral and stromal CD8+ and FoxP3+ lymphocyte counts correlated with tumoral PDL1 expression, which is supportive of an adaptive immune response. PDL1 expression in desmoplastic melanoma was associated with tumor aggressiveness and progression. Although PDL1 expression is typically low in melanoma, its frequency and level of expression in desmoplastic melanoma may identify a subset of melanomas that are likely to respond to immunotherapy.
引用
- Kraft S, Fernandez-Figueras MT, Richarz NA, et al. PDL1 expression in desmoplastic melanoma is associated with tumor aggressiveness and progression. J Am Acad Dermatol. 2017. PMID: 28728868. doi:10.1016/j.jaad.2017.05.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。